TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Harrow Health ( (HROW) ).
Harrow Health announced its financial results for the third quarter of 2025, reporting a 45% increase in total revenues to $71.6 million compared to the same period last year. The company achieved a GAAP net income of $1.0 million and an adjusted EBITDA of $22.7 million. Significant strategic initiatives included the launch of TRIESENCE® into its largest market, the upcoming rollout of the Harrow Access for All program, and the expansion of its commercial leadership team. Harrow also entered into coverage agreements for VEVYE with several leading national payers, enhancing its market positioning. Additionally, Harrow announced the acquisition of Melt Pharmaceuticals, Inc., aiming to expand its product offerings with Melt’s innovative non-opioid, non-IV sedation therapies.
The most recent analyst rating on (HROW) stock is a Sell with a $32.00 price target. To see the full list of analyst forecasts on Harrow Health stock, see the HROW Stock Forecast page.
Spark’s Take on HROW Stock
According to Spark, TipRanks’ AI Analyst, HROW is a Underperform.
Harrow Health’s overall stock score is primarily impacted by its financial performance and valuation. The company’s high leverage, negative returns on equity, and cash flow challenges pose significant financial risks. Additionally, the negative P/E ratio and lack of dividend yield further detract from its valuation appeal. Technical analysis indicates bearish momentum, adding to the cautious outlook. Despite positive strategic developments noted in the earnings call, these factors weigh heavily on the overall score.
To see Spark’s full report on HROW stock, click here.
More about Harrow Health
Harrow, Inc. (Nasdaq: HROW) is a leading provider of ophthalmic disease management solutions in North America, offering a comprehensive portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet (or neovascular) age-related macular degeneration, cataracts, refractive errors, glaucoma, and a range of other ocular surface conditions and retina diseases.
Average Trading Volume: 735,982
Technical Sentiment Signal: Buy
Current Market Cap: $1.26B
See more insights into HROW stock on TipRanks’ Stock Analysis page.